Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07052448
Enrolling by invitation Observational

The Efficacy of Sequential RT After Triple Therapy for uHCC

NCT07052448 · tracked via the Priya Life Science China tracker
Sponsor
Fujian Provincial Hospital
Phase
Observational
Started
2020-11-01
Last updated
2025-07-04

Condition(s) studied

Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies

sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies: sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies

Study summary

Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and many patients fail to achieve complete necrosis of the lesions after treatment. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with HCC and assessed as unresectable by multidisciplinary team (MDT) * Patients who achieved PR or SD after triple therapy according to the mRECIST and did not meet the criteria for radical surgical resection or could not tolerate surgical treatment * Patients who received sequential radiotherapy * Age between 18 and 75 years * Child-Pugh class A or B * Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1 Exclusion Criteria: * Previous acceptance of other antitumor treatments * Treatment in conjunction with other treatment regimens, such as radiofrequency ablation and chemotherapy * History of other malignancies * Incomplete data.

Primary outcome measure(s)

  • OS — From date of randomization until the date of date of death from any cause or the most recent follow-up, whichever came first, assessed up to 100 months
    overall survival

Trial sites (1)

FacilityCityRegionStatus
Fuzhou University Affiliated Provincial Hospital Fuzhou Fujian

More Fujian Provincial Hospital trials in China

Personalized Interventions Via Health Portraits in Mild Behavioral Impairment Recruiting
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer Recruiting
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC Recruiting
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy Enrolling by invitation
Moderate-Intensity Aerobic Calisthenics for Rural Elderly With Motoric Cognitive Risk Syndrome Starting soon

Other trials for the same condition

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3 Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma Recruiting
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07052448 on ClinicalTrials.gov ↗ ← All trials in China